CA Patent

CA2622352C — Substituted pyrazole compounds

Assigned to Miikana Therapeutics Inc · Expires 2014-05-27 · 12y expired

What this patent protects

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Wherein the compound of that which is disclosed has the formula of: (see above formula)…

USPTO Abstract

Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Wherein the compound of that which is disclosed has the formula of: (see above formula) Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
CA2622352C
Jurisdiction
CA
Classification
—
Expires
2014-05-27
Drug substance claim
No
Drug product claim
No
Assignee
Miikana Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.